Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Trial Details

NCT ID
NCT07165132
Phase
PHASE1
Sponsor
RayzeBio, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • RYZ401
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • St Louis, Missouri, United States|38.62727,-90.19789
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • At least 18 years old at the time of signing the main study informed consent form (ICF).
  • Histologically confirmed:
  • Dose Escalation (all cohorts): Grades 1-3 WD, metastatic or locally advanced and unresectable NET at any primary site, including, but not limited t…
  • Dose Expansion Cohort A: Grades 1-3 WD, metastatic or locally advanced and unresectable GEP-NETs

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →